Literature DB >> 16669844

The implications of a growing evidence base for drug use in elderly patients. Part 4. Vitamin D and bisphosphonates for fractures and osteoporosis.

J K Dhesi1, T J Allain, A A Mangoni, S H D Jackson.   

Abstract

Fractures are common in elderly subjects, disabling and occasionally fatal. Their incidence increases exponentially with age, with the commonest affected sites being the wrist, vertebrae, hip and humerus. Of these, hip fractures are the most relevant in terms of morbidity and financial cost. The increase in fracture rate with age is believed to result predominantly from age-related increases in the incidence of osteoporosis and falls. This article reviews the evidence for the use of vitamin D and bisphosphonates for the prevention of bone fractures and osteoporosis in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16669844      PMCID: PMC1885055          DOI: 10.1111/j.1365-2125.2006.02612.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.

Authors:  N B Watts; S T Harris; H K Genant; R D Wasnich; P D Miller; R D Jackson; A A Licata; P Ross; G C Woodson; M J Yanover
Journal:  N Engl J Med       Date:  1990-07-12       Impact factor: 91.245

2.  Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with vitamin D status.

Authors:  J K Dhesi; L M Bearne; C Moniz; M V Hurley; S H D Jackson; C G Swift; T J Allain
Journal:  J Bone Miner Res       Date:  2002-05       Impact factor: 6.741

3.  Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

Authors:  J Reginster; H W Minne; O H Sorensen; M Hooper; C Roux; M L Brandi; B Lund; D Ethgen; S Pack; I Roumagnac; R Eastell
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

4.  Inclusion of older women in randomized clinical trials: factors associated with taking study medication in the fracture intervention trial.

Authors:  D S Buist; A Z LaCroix; D M Black; F Harris; J Blank; K Ensrud; D Edgerton; S Rubin; K M Fox
Journal:  J Am Geriatr Soc       Date:  2000-09       Impact factor: 5.562

5.  Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.

Authors:  Steven Boonen; Michael R McClung; Richard Eastell; Ghada El-Hajj Fuleihan; Ian P Barton; Pierre Delmas
Journal:  J Am Geriatr Soc       Date:  2004-11       Impact factor: 5.562

6.  Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women.

Authors:  M Pfeifer; B Begerow; H W Minne; C Abrams; D Nachtigall; C Hansen
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

7.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

8.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Authors:  M R McClung; P Geusens; P D Miller; H Zippel; W G Bensen; C Roux; S Adami; I Fogelman; T Diamond; R Eastell; P J Meunier; J Y Reginster
Journal:  N Engl J Med       Date:  2001-02-01       Impact factor: 91.245

9.  Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial.

Authors:  Daksha P Trivedi; Richard Doll; Kay Tee Khaw
Journal:  BMJ       Date:  2003-03-01

10.  Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study.

Authors:  J D Ringe; A Dorst; H Faber; K Ibach
Journal:  Rheumatol Int       Date:  2003-09-10       Impact factor: 2.631

View more
  1 in total

Review 1.  Prescribing for older people.

Authors:  James C Milton; Ian Hill-Smith; Stephen H D Jackson
Journal:  BMJ       Date:  2008-03-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.